Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Pigment Cell Melanoma Res. 2020 Jul 7;33(6):878–888. doi: 10.1111/pcmr.12909

Figure 3: Gene Mutation Profiles.

Figure 3:

(3A): Proportion of NRAS positive (+) and NRAS WT in responders to immunotherapy compared to patients with SD or PD. A greater proportion of responders to immunotherapy were NRAS positive compared to patients with SD or PD (p=0.050). (3B): Proportion of BRAF positive (+) and BRAF WT in responders to immunotherapy compared to BRAF + and BRAF WT patients with SD or PD (p=0.423).